Prothioconazole

Synonyms: JAU-6476
Prothioconazole (JAU-6476) 是一种具有口服活性的广谱杀真菌剂,可微弱抑制白色念珠菌 (Candida albicans) 的 CaCYP51 活性(表观 IC50 约为 120 μM),通过降低 α-微管蛋白乙酰化水平破坏微管 (Microtubule) 稳定性,诱导线粒体功能障碍 (Mitochondrial dysfunction)、氧化应激、DNA 损伤和细胞凋亡 (Apoptosis),并在细胞、培养基、植物和动物体内累积 14-甲基化固醇、消耗麦角固醇,同时干扰小鼠肝脏丙酮酸代谢和糖酵解/糖异生过程、下调 Fasn mRNA 表达、诱导肝毒性和肾脏代谢紊乱、降低雌性小鼠的生育能力、抑制小鼠体重增长及升高肝/肾指数,可用于念珠菌病的相关研究。
产品编号: MS-X03245 纯度: 99.52% CAS No.: 178928-70-6 分子式: C14H15Cl2N3Os 分子量: 344.26
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

Prothioconazole (JAU-6476) 是一种具有口服活性的广谱杀真菌剂,可微弱抑制白色念珠菌 (Candida albicans) 的 CaCYP51 活性(表观 IC50 约为 120 μM),通过降低 α-微管蛋白乙酰化水平破坏微管 (Microtubule) 稳定性,诱导线粒体功能障碍 (Mitochondrial dysfunction)、氧化应激、DNA 损伤和细胞凋亡 (Apoptosis),并在细胞、培养基、植物和动物体内累积 14-甲基化固醇、消耗麦角固醇,同时干扰小鼠肝脏丙酮酸代谢和糖酵解/糖异生过程、下调 Fasn mRNA 表达、诱导肝毒性和肾脏代谢紊乱、降低雌性小鼠的生育能力、抑制小鼠体重增长及升高肝/肾指数,可用于念珠菌病的相关研究。

生物实验数据

生物活性 Prothioconazole (JAU-6476) is an orally active broad-spectrum fungicide that weakly inhibits CaCYP51 activity in Candida albicans with an apparent IC50 of approximately 120 μM, disrupts microtubule stability by reducing α-tubulin acetylation levels, induces mitochondrial dysfunction, oxidative stress, DNA damage, and apoptosis, accumulates 14-methylated sterols and depletes ergosterol in cells, culture media, plants, and animals, interferes with hepatic pyruvate metabolism and glycolysis/gluconeogenesis in mice, downregulates Fasn mRNA expression, induces hepatotoxicity and renal metabolic disorders, reduces fertility in female mice, inhibits body weight gain and increases liver/kidney indices in mice, and can be used for research related to candidiasis.
IC50 & Target

CYP51

 

体外研究
(In Vitro)

Prothioconazole 与纯化的白色念珠菌 CaCYP51 结合能力较弱,其表观解离常数 Kd 为 6.3 μM,产生的是 I 型差光谱,而非唑类抗真菌剂典型的 II 型差光谱。
Prothioconazole (100 μM) 可竞争性抑制 Lanosterol (MS-Z67160) 与纯化的白色念珠菌 CaCYP51 的结合,使 Lanosterol 的表观 Ks 升高 2.5 倍至 62.2 μM。
Prothioconazole (0-100 μM) 可微弱抑制无细胞体系中白色念珠菌 (Candida albicans) 的 CaCYP51 活性,其表观 IC50 约为 120 μM,在 100 μM 浓度下仅能达到 45% 的抑制率。

体内研究
(In Vivo)

Prothioconazole (10 mg/kg/天;口服;每日;持续 30 天) 暴露可通过线粒体功能障碍、氧化应激、DNA 损伤及凋亡途径破坏雌性小鼠的卵母细胞成熟、受精和早期胚胎发育,从而诱导生殖毒性,使后代数量减少约 34%。
Prothioconazole (1-5 mg/kg BW/day;口服;每日;连续 28 天) 对雄性 ICR 小鼠给药后,会引发剂量依赖性的氧化应激、代谢紊乱及生长表型减退,且肝脏组织中的损伤效应较肾脏组织更为显著。
Prothioconazole (口服,每日 1 次,连续 30 天,剂量 1-5 mg/kg) 可在雌性 ICR 小鼠中诱导剂量依赖性的肝脏代谢功能障碍和肝毒性,通过改变关键基因表达、代谢物水平及肝脏组织学特征破坏糖脂代谢。

Animal Model: ICR (female, 6-8-week-old)
Dosage: 1 mg/kg/day; 5 mg/kg/day; 10 mg/kg/day
Administration: p.o.; daily; 30 days
Result: Reduced germinal vesicle breakdown (GVBD) rate to 75.3% (control: 89.5%).
Reduced first polar body extrusion (PBE) rate to 48.3% (control: 78.5%).
Reduced number of ovulated oocytes to 39.7 (control: 55.2).
Reduced fertilization rate to 78.5% (control: 95.9%).
Reduced 8-cell embryo rate to 52.6% (control: 63.8%).
Reduced morula rate to 35.1% (control: 61.2%).
Reduced blastocyst rate to 7.2% (control: 36.7%).
Reduced average offspring number to 10.1 (control: 15.3).
Increased aberrant spindle rate to 52.9% (control: 22.2%).
Increased misaligned chromosome rate to 28.6% (control: 15.9%).
Reduced acetylated α-tubulin fluorescence intensity to 15.4 A.U. (control: 32.2 A.U.).
Increased defective kinetochore-microtubule attachments rate to 46.1% (control: 14.3%).
Reduced Juno fluorescence intensity to 24.5 A.U. (control: 34.4 A.U.).
Reduced cortical granule fluorescence intensity to 28.7 A.U. (control: 40.7 A.U.).
Reduced ovastacin fluorescence intensity to 38.7 A.U. (control: 58.7 A.U.).
Reduced sperm binding number to 89.3 per egg (control: 143.8 per egg).
Reduced mitochondrial fluorescence intensity to 18.3 A.U. (control: 27.5 A.U.).
Increased ROS fluorescence intensity to 17.85 A.U. (control: 2.5 A.U.).
Increased γ-H2A.X fluorescence intensity to 21.5 A.U. (control: 13.4 A.U.).
Increased Annexin-V fluorescence intensity to 12.3 A.U. (control: 3.8 A.U.).
Identified 719 downregulated and 528 upregulated differentially expressed genes in oocytes, enriched in pathways related to mitochondrial oxidative phosphorylation, apoptosis, and oocyte meiosis.
Animal Model: ICR (5-week-old male)
Dosage: 1 mg/kg BW/day; 5 mg/kg BW/day
Administration: p.o.; daily; 28 days
Result: Significantly decreased body weight gain and liver weight at both doses.
Significantly decreased liver index at 1 mg/kg dose; significantly decreased liver index, kidney weight, and kidney index at 5 mg/kg dose.
Did not significantly reduce body weight at either dose.
Significantly decreased glutathione (GSH) content in liver at both doses.
Significantly increased lipid peroxidation (LPO) content, superoxide dismutase (SOD) activity, and malondialdehyde (MDA) content in liver at 5 mg/kg dose; did not significantly increase LPO content in liver at 1 mg/kg dose.
Caused no significant changes to catalase (CAT) or peroxidase (POD) activity in liver at either dose.
Caused no significant changes to oxidative stress biomarkers in kidney at either dose.
Significantly increased relative abundances of lipid, lactate, acetate, choline, leucine, glutamate, glutamine, succinate, valine, alanine, lysine, and uracil in liver at both doses; significantly decreased relative abundances of phosphocholine (PC), glycerophosphocholine (GPC), and glycogen in liver at both doses.
Additionally significantly decreased relative abundances of alpha-glucose, beta-glucose, and betaine, and increased relative abundance of taurine in liver at 5 mg/kg dose.
Significantly decreased relative abundance of taurine in kidney at 1 mg/kg dose; significantly increased relative abundances of choline, PC, and glutamine, and decreased relative abundances of lactate, acetate, leucine, taurine, betaine, and succinate in kidney at 5 mg/kg dose.
Significantly altered D-glutamine and D-glutamate metabolism, alanine-aspartate-glutamate metabolism, pyruvate metabolism, and arginine biosynthesis in liver tissue at both doses.
Significantly altered phenylalanine, tyrosine, and tryptophan biosynthesis in kidney tissue at both doses; additionally significantly altered pyruvate metabolism, arginine biosynthesis, and taurine and hypotaurine metabolism in kidney tissue at 5 mg/kg dose.
性状 固体
颜色 White to light yellow

化学信息

分子量 344.26
分子式 C14H15Cl2N3Os
CAS No. 178928-70-6
别名 JAU-6476

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.81 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (145.24 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.9048 mL14.5239 mL29.0478 mL72.6195 mL
5 mM0.5810 mL2.9048 mL5.8096 mL14.5239 mL
10 mM0.2905 mL1.4524 mL2.9048 mL7.2620 mL
15 mM0.1937 mL0.9683 mL1.9365 mL4.8413 mL
20 mM0.1452 mL0.7262 mL1.4524 mL3.6310 mL
25 mM0.1162 mL0.5810 mL1.1619 mL2.9048 mL
30 mM0.0968 mL0.4841 mL0.9683 mL2.4207 mL
40 mM0.0726 mL0.3631 mL0.7262 mL1.8155 mL
50 mM0.0581 mL0.2905 mL0.5810 mL1.4524 mL
60 mM0.0484 mL0.2421 mL0.4841 mL1.2103 mL
80 mM0.0363 mL0.1815 mL0.3631 mL0.9077 mL
100 mM0.0290 mL0.1452 mL0.2905 mL0.7262 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础